Table 2 Pathological characters and treatments of patients with stage I OEC
From: Prognostic analysis for Chinese patients with stage I ovarian endometrioid carcinoma
EOC | |
|---|---|
Total number | 78 |
Tumor size(cm) | |
Median [IQR] | 8 (6,12) |
Range | 2.0–25.0 |
Side of ovarian tumor | |
Unilateral | 63 (80.8%) |
Bilateral | 15 (19.2%) |
Ascitesb | |
Positive | 8 (10.3%) |
Negative | 70 (89.7%) |
Grade | |
1 | 35 (44.9%) |
2 | 26 (33.3%) |
3 | 17 (21.8%) |
Mixed histologyc | |
Yes | 5 (6.4%) |
No | 73 (93.6%) |
EM associated | |
Yes | 23 (29.5%) |
No | 55 (70.5%) |
Endometrial disordersf | |
Yes | 21 (26.9%) |
No | 57 (51.1%) |
ER presentatione | |
Number | 37 |
Positive | 25 (67.6%) |
Negative | 12 (32.4%) |
PR presentatione | |
Number | 37 |
Positive | 29 (78.4%) |
Negative | 8 (21.6%) |
Residual disease | |
No or <1 cm | 77 (98.7%) |
> 1 cm | 1 (1.3%) |
Lymphadenectomy | |
Yes | 72 (97.4%) |
No | 6 (2.6%) |
Para-aortic lymphadenectomya | |
Number | 72 |
Yes | 45 (62.5%) |
No | 27 (37.5%) |
Numbers of lymph nodes dissected | |
Number | 72 |
Median(IQR, number) | 18 [11,27] |
Range (number) | 2–48 |
Chemotherapy | |
Yes | 70 (89.8%) |
No | 5 (6.4%) |
Unclear | 3 (3.8%) |
Chemotherapy regimen | |
Number | 70 |
Platinum based | 68 (97.1%) |
Others | 2 (2.9%) |
Platinum chemotherapy cycle | |
Number | 68 |
< 4 | 21 (30.9%) |
> =4 | 47 (69.1%) |
Platinum-resistance | |
Number | 68 |
Yes | 3 (4.3%) |
No | 65 (95.7%) |